Concord Biotech Limited
Momentum (79/100) does the heavy lifting; financial trend (0/100) is the drag.
Fair valueOvervaluedOur blended model reads Concord Biotech Limited as a Hold at 45/100. At ₹1,420.8 it trades above our blended DCF and relative-multiples fair value of ₹942.48, about 34% downside to that estimate — we read it as overvalued by 34%. On 50.5x trailing earnings it sits pricier than the Healthcare median of about 37.6x. The price is about 19% below its 52-week high of ₹1,745.95 and 41% above the low of ₹1,008.76. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,216 implies about 14% downside across 5 analysts. It clears 7 of 13 investability checks, with durability 78, valuation 40 and momentum 79 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹753.99.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-18.62% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold45Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Fail: ROE above 15%: 13.5%
- Pass: Low debt (D/E < 0.5): 0.00x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -24%
- Fail: Earnings growing: -37%
- Pass: Net margin ≥ 10%: 24.7%
- Pass: Current ratio > 1.5: 7.39
- Fail: Below our fair value
- Fail: Margin of safety ≥ 20%
- Pass: Above 200-day average
- Pass: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 37.93
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter72.5%
- Institutions12.8%
- Public & other14.7%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (24.7%).
- Financially solid — Altman Z 37.93.
Bear case
Threats
- Earnings contracting year on year.
- Trades ~34% above our estimated fair value.
About Concord Biotech Limited
Concord Biotech Limited develops, manufactures, and sells pharmaceutical products in India and internationally, with a focus on fermentation-based active pharmaceutical ingredients across immunosuppressants, anti-bacterial, oncology, and antifungal therapeutic areas. The company provides specific immunosuppressant drugs including tacrolimus, mycophenolate mofetil, mycophenolate sodium, cyclosporine, sirolimus, voclosporin, and pimecrolimus.
Concord Biotech Limited — frequently asked questions
Is Concord Biotech Limited a buy, hold or sell?
StocksWizard currently rates Concord Biotech Limited (CONCORDBIO) a Hold, based on a blended score of 45/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is Concord Biotech Limited's fair value?
Our blended DCF and relative-valuation model estimates Concord Biotech Limited's fair value at about ₹942.48, versus a current price of ₹1,420.8 — roughly 34% downside. On that basis the stock looks overvalued by 34%.
Is Concord Biotech Limited financially healthy?
Concord Biotech Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has Concord Biotech Limited's share price performed?
Concord Biotech Limited is up 21% over three months, and last traded at ₹1,420.8. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.